- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 16h ago↗ source
- STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptidesThe panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.STAT · 20h ago↗ source
- FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157An FDA advisory committee voted Thursday to recommend expanding access to a popular peptide used by health and wellness enthusiasts for repairing muscles and healing injuries. The recommendation se…